8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 12, 2026·SEC
AtriCure, Inc.(ATRC)Earnings, Financials & Key Ratios
ATRC•NASDAQ
$28.01
$1.42B mkt cap·Price updated May 6, 2026
AboutAtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Show more
- Revenue$535M+14.9%
- EBITDA$17M+180.3%
- Net Income-$11M+74.4%
- EPS (Diluted)-0.24+74.7%
- Gross Margin74.41%-0.4%
- EBITDA Margin3.2%+169.9%
- Operating Margin-0.64%+92.5%
- Net Margin-2.14%+77.7%
- ROE-2.4%+75.1%
- ROIC-0.63%+90.9%
- Debt/Equity0.18+7.8%
- Interest Coverage-0.73+87.5%
ATRC Key Insights
AtriCure, Inc. (ATRC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 25.0%
- ✓Strong 5Y sales CAGR of 20.9%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ATRC Price & Volume
AtriCure, Inc. (ATRC) stock price & volume — 10-year historical chart
Loading chart...
ATRC Growth Metrics
AtriCure, Inc. (ATRC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years15.21%
5 Years20.95%
3 Years17.4%
TTM15.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM87.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.93%
Return on Capital
10 Years-5.68%
5 Years-2.38%
3 Years-4.36%
Last Year-0.62%
ATRC Recent Earnings
AtriCure, Inc. (ATRC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026EPS
$0.00
Est $0.07
+103.1%
Revenue
$141M
Est $140M
+1.1%
Q1 2026
Feb 17, 2026EPS
$0.06
Est $0.04
+249.9%
Revenue
$141M
Est $140M
+0.6%
Q4 2025
Oct 29, 2025EPS
$0.01
Est $0.11
+90.9%
Revenue
$134M
Est $141M
-4.4%
Q3 2025
Jul 29, 2025EPS
$0.02
Est $0.15
+86.7%
Revenue
$136M
Est $130M
+4.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.00vs $0.07+103.1% | $141Mvs $140M+1.1% |
| Q1 2026 | Feb 17, 2026 | $0.06vs $0.04+249.9% | $141Mvs $140M+0.6% |
| Q4 2025 | Oct 29, 2025 | $0.01vs $0.11+90.9% | $134Mvs $141M-4.4% |
| Q3 2025 | Jul 29, 2025 | $0.02vs $0.15+86.7% | $136Mvs $130M+4.6% |
Based on last 12 quarters of dataView full earnings history →
ATRC Peer Comparison
AtriCure, Inc. (ATRC) competitors in Surgical and interventional devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 IRTC | 3.87B | 117.70 | -84.68 | 26.24% | -3.53% | -20.6% | 4.79 | |
 BEAT | 34.34M | 0.86 | -1.38 | -5.71% | ||||
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 JNJ | 541.31B | 224.62 | 38.79 | 4.3% | 27.26% | 31.69% | 0.51 | |
 EW | 47.97B | 83.20 | 45.46 | 11.55% | 17.64% | 10.35% | 0.07 |
Compare ATRC vs Peers
AtriCure, Inc. (ATRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATRC Income Statement
AtriCure, Inc. (ATRC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 174.72M | 201.63M | 230.81M | 206.53M | 274.33M | 330.38M | 399.25M | 465.31M | 534.53M | 552.16M |
| Revenue Growth % | 12.64% | 15.4% | 14.47% | -10.52% | 32.83% | 20.43% | 20.84% | 16.55% | 14.88% | 15.01% |
| Cost of Goods Sold | 48.55M | 54.51M | 60.47M | 57.22M | 68.47M | 84.44M | 98.88M | 117.78M | 136.79M | 135.46M |
| COGS % of Revenue | 27.79% | 27.03% | 26.2% | 27.71% | 24.96% | 25.56% | 24.77% | 25.31% | 25.59% | - |
| Gross Profit | 126.16M▲ 0% | 147.12M▲ 16.6% | 170.34M▲ 15.8% | 149.31M▼ 12.3% | 205.86M▲ 37.9% | 245.94M▲ 19.5% | 300.37M▲ 22.1% | 347.52M▲ 15.7% | 397.74M▲ 14.4% | 416.7M▲ 0% |
| Gross Margin % | 72.21% | 72.97% | 73.8% | 72.29% | 75.04% | 74.44% | 75.23% | 74.69% | 74.41% | 75.47% |
| Gross Profit Growth % | 13.56% | 16.61% | 15.78% | -12.34% | 37.88% | 19.47% | 22.13% | 15.7% | 14.45% | - |
| Operating Expenses | 151.14M | 164.25M | 203.46M | 193.54M | 150.66M | 288.61M | 327.05M | 387.54M | 401.19M | 418.67M |
| OpEx % of Revenue | 86.51% | 81.46% | 88.15% | 93.71% | 54.92% | 87.36% | 81.92% | 83.29% | 75.05% | - |
| Selling, General & Admin | 117M | 129.52M | 162.23M | 150.47M | 204.65M | 231.27M | 253.14M | 291.36M | 311.02M | 319.51M |
| SG&A % of Revenue | 66.96% | 64.24% | 70.29% | 72.86% | 74.6% | 70% | 63.4% | 62.62% | 58.19% | - |
| Research & Development | 34.14M | 34.72M | 41.23M | 43.07M | 48.51M | 57.34M | 73.92M | 96.18M | 90.17M | 99.16M |
| R&D % of Revenue | 19.54% | 17.22% | 17.86% | 20.85% | 17.68% | 17.35% | 18.51% | 20.67% | 16.87% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -102.5M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.98M▲ 0% | -17.13M▲ 31.4% | -33.12M▼ 93.4% | -44.23M▼ 33.5% | 55.2M▲ 224.8% | -42.67M▼ 177.3% | -26.68M▲ 37.5% | -40.01M▼ 50.0% | -3.45M▲ 91.4% | -1.97M▲ 0% |
| Operating Margin % | -14.3% | -8.49% | -14.35% | -21.42% | 20.12% | -12.92% | -6.68% | -8.6% | -0.64% | -0.36% |
| Operating Income Growth % | 19.78% | 31.43% | -93.39% | -33.55% | 224.81% | -177.29% | 37.47% | -49.96% | 91.39% | - |
| EBITDA | -15.85M | -8.37M | -23.76M | -34.69M | 65.65M | -30.96M | -11.87M | -21.28M | 17.08M | 13.48M |
| EBITDA Margin % | -9.07% | -4.15% | -10.29% | -16.79% | 23.93% | -9.37% | -2.97% | -4.57% | 3.2% | 2.44% |
| EBITDA Growth % | 27.42% | 47.18% | -183.72% | -46.01% | 289.26% | -147.16% | 61.66% | -79.28% | 180.28% | 162.32% |
| D&A (Non-Cash Add-back) | 9.13M | 8.75M | 9.37M | 9.55M | 10.44M | 11.71M | 14.81M | 18.73M | 20.53M | 15.45M |
| EBIT | -24.61M | -16.3M | -30.88M | -43.16M | 55.3M | -41.21M | -22.92M | -37.27M | -4.29M | 2.25M |
| Net Interest Income | -2.04M | -3.6M | -1.71M | -3.78M | -4.45M | -2.99M | -3.13M | -1.97M | -1.4M | -1.65M |
| Interest Income | 227K | 1.01M | 2.4M | 1.1M | 466K | 1.99M | 3.79M | 4.43M | 4.48M | 4.25M |
| Interest Expense | 2.26M | 4.61M | 4.11M | 4.88M | 4.92M | 4.99M | 6.92M | 6.41M | 5.88M | 5.9M |
| Other Income/Expense | -1.9M | -3.78M | -1.87M | -3.81M | -4.82M | -3.53M | -3.16M | -3.66M | -6.72M | -1.29M |
| Pretax Income | -26.88M▲ 0% | -20.91M▲ 22.2% | -34.99M▼ 67.4% | -48.04M▼ 37.3% | 50.39M▲ 204.9% | -46.2M▼ 191.7% | -29.85M▲ 35.4% | -43.67M▼ 46.3% | -10.16M▲ 76.7% | -3.26M▲ 0% |
| Pretax Margin % | -15.38% | -10.37% | -15.16% | -23.26% | 18.37% | -13.98% | -7.48% | -9.39% | -1.9% | -0.59% |
| Income Tax | 14K | 226K | 199K | 114K | 188K | 268K | 591K | 1.02M | 1.28M | 1.33M |
| Effective Tax Rate % | -0.05% | -1.08% | -0.57% | -0.24% | 0.37% | -0.58% | -1.98% | -2.34% | -12.64% | -40.85% |
| Net Income | -26.89M▲ 0% | -21.14M▲ 21.4% | -35.19M▼ 66.5% | -48.16M▼ 36.8% | 50.2M▲ 204.2% | -46.47M▼ 192.6% | -30.44M▲ 34.5% | -44.7M▼ 46.8% | -11.45M▲ 74.4% | -4.59M▲ 0% |
| Net Margin % | -15.39% | -10.48% | -15.25% | -23.32% | 18.3% | -14.06% | -7.62% | -9.61% | -2.14% | -0.83% |
| Net Income Growth % | 19.34% | 21.4% | -66.5% | -36.83% | 204.24% | -192.56% | 34.49% | -46.85% | 74.39% | 87.97% |
| Net Income (Continuing) | -26.89M | -21.14M | -35.19M | -48.16M | 50.2M | -46.47M | -30.44M | -44.7M | -11.45M | -4.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.83▲ 0% | -0.62▲ 25.3% | -0.94▼ 51.6% | -1.14▼ 21.3% | 1.09▲ 195.6% | -1.02▼ 193.6% | -0.66▲ 35.3% | -0.95▼ 43.9% | -0.24▲ 74.7% | -0.09▲ 0% |
| EPS Growth % | 20.95% | 25.3% | -51.61% | -21.28% | 195.61% | -193.58% | 35.29% | -43.94% | 74.74% | 87.93% |
| EPS (Basic) | -0.83 | -0.62 | -0.94 | -1.14 | 1.11 | -1.02 | -0.66 | -0.95 | -0.24 | - |
| Diluted Shares Outstanding | 32.39M | 34.09M | 37.59M | 42.13M | 46.04M | 45.74M | 46.31M | 46.97M | 47.75M | 49.05M |
| Basic Shares Outstanding | 32.39M | 34.09M | 37.59M | 42.13M | 45.07M | 45.74M | 46.31M | 46.97M | 47.75M | 48.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATRC Balance Sheet
AtriCure, Inc. (ATRC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 82.26M | 174.67M | 143.16M | 306.74M | 196.08M | 215.21M | 266.25M | 267.83M | 322.52M | 313.69M |
| Cash & Short-Term Investments | 34.45M | 124.4M | 81.8M | 244.22M | 119.09M | 121.11M | 137.28M | 122.72M | 167.43M | 146.16M |
| Cash Only | 21.81M | 32.23M | 28.48M | 41.94M | 43.65M | 58.1M | 84.31M | 122.72M | 167.43M | 146.16M |
| Short-Term Investments | 12.64M | 92.17M | 53.32M | 202.27M | 75.44M | 63.01M | 52.98M | 0 | 0 | 0 |
| Accounts Receivable | 23.08M | 25.2M | 28.05M | 23.15M | 33.02M | 42.69M | 52.5M | 60.34M | 66.65M | 71.31M |
| Days Sales Outstanding | 48.22 | 45.61 | 44.35 | 40.91 | 43.94 | 47.17 | 48 | 47.33 | 45.51 | 44.12 |
| Inventory | 22.45M | 22.48M | 29.41M | 35.03M | 38.96M | 45.93M | 67.9M | 75.33M | 78.49M | 81.14M |
| Days Inventory Outstanding | 168.78 | 150.55 | 177.54 | 223.42 | 207.71 | 198.54 | 250.64 | 233.46 | 209.44 | 212.15 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 8.56M | 9.43M | 9.94M | 15.07M |
| Total Non-Current Assets | 185.45M | 182.09M | 414.72M | 407.8M | 419.24M | 370.23M | 347.69M | 341.5M | 331.66M | 330.3M |
| Property, Plant & Equipment | 28.75M | 27.08M | 36.68M | 30.2M | 36.17M | 42.62M | 46.76M | 47.39M | 45.99M | 46.19M |
| Fixed Asset Turnover | 6.08x | 7.45x | 6.29x | 6.84x | 7.58x | 7.75x | 8.54x | 9.82x | 11.62x | 11.86x |
| Goodwill | 105.26M | 105.26M | 234.78M | 234.78M | 234.78M | 234.78M | 234.78M | 234.78M | 282.81M | 280.42M |
| Intangible Assets | 50.76M | 49.25M | 129.88M | 128.2M | 42.99M | 39.34M | 63.99M | 56.47M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 12.68M | 14.18M | 104.34M | 51.51M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 676K | 495K | 705K | 440K | 955K | 1.99M | 2.16M | 2.87M | 2.86M | 12.41M |
| Total Assets | 267.7M▲ 0% | 356.76M▲ 33.3% | 557.88M▲ 56.4% | 714.54M▲ 28.1% | 615.31M▼ 13.9% | 585.45M▼ 4.9% | 613.93M▲ 4.9% | 609.33M▼ 0.7% | 654.18M▲ 7.4% | 643.99M▲ 0% |
| Asset Turnover | 0.65x | 0.57x | 0.41x | 0.29x | 0.45x | 0.56x | 0.65x | 0.76x | 0.82x | 0.87x |
| Asset Growth % | -3.15% | 33.27% | 56.37% | 28.08% | -13.89% | -4.85% | 4.87% | -0.75% | 7.36% | 21.46% |
| Total Current Liabilities | 31.9M | 40.22M | 49.92M | 49.14M | 56.45M | 58.39M | 74.57M | 73.42M | 81.52M | 73.19M |
| Accounts Payable | 12.43M | 9.66M | 14.95M | 12.74M | 18.6M | 19.9M | 27.35M | 25.03M | 78.4M | 0 |
| Days Payables Outstanding | 93.45 | 64.68 | 90.22 | 81.24 | 99.14 | 86.01 | 100.98 | 77.57 | 209.19 | 87.27 |
| Short-Term Debt | 561K | 4.72M | 2.22M | 6.67M | 0 | 3.33M | 2.53M | 2.81M | 3.12M | 0 |
| Deferred Revenue (Current) | 634K | 886K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.09M | 12.23M | 5.64M | 9.14M | 33.41M | 2.8M | 2.75M | 45.59M | 0 | 73.19M |
| Current Ratio | 2.58x | 4.34x | 2.87x | 6.24x | 3.47x | 3.69x | 3.57x | 3.65x | 3.96x | 3.96x |
| Quick Ratio | 1.87x | 3.78x | 2.28x | 5.53x | 2.78x | 2.90x | 2.66x | 2.62x | 2.99x | 2.99x |
| Cash Conversion Cycle | 123.55 | 131.49 | 131.67 | 183.09 | 152.51 | 159.7 | 197.66 | 203.22 | 45.76 | 169 |
| Total Non-Current Liabilities | 74.64M | 67.16M | 260.62M | 253.01M | 75.11M | 70.3M | 73.19M | 74.94M | 80.72M | 79.1M |
| Long-Term Debt | 24.1M | 35.57M | 59.63M | 53.44M | 59.74M | 56.83M | 60.59M | 61.87M | 73.38M | 71.78M |
| Capital Lease Obligations | 12.76M | 12.17M | 14.57M | 12.15M | 14.15M | 12.24M | 11.37M | 11.86M | 11.52M | 35.86M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 37.77M | 19.42M | 186.42M | 187.42M | 1.22M | 1.23M | 1.23M | 1.21M | -4.17M | 11.68M |
| Total Liabilities | 106.54M | 107.38M | 310.54M | 302.14M | 131.56M | 128.69M | 147.76M | 148.36M | 162.24M | 152.29M |
| Total Debt | 37.42M | 52.46M | 76.42M | 74M | 75.65M | 74.55M | 74.49M | 76.53M | 88.02M | 71.78M |
| Net Debt | 15.61M | 20.23M | 47.94M | 32.06M | 31.99M | 16.45M | -9.82M | -46.19M | -79.41M | -74.38M |
| Debt / Equity | 0.23x | 0.21x | 0.31x | 0.18x | 0.16x | 0.16x | 0.16x | 0.17x | 0.18x | 0.18x |
| Debt / EBITDA | - | - | - | - | 1.15x | - | - | - | 5.15x | 5.33x |
| Net Debt / EBITDA | - | - | - | - | 0.49x | - | - | - | -4.65x | -4.65x |
| Interest Coverage | -10.87x | -3.54x | -7.51x | -8.83x | 11.25x | -8.27x | -3.31x | -5.82x | -0.73x | 0.38x |
| Total Equity | 161.17M▲ 0% | 249.38M▲ 54.7% | 247.34M▼ 0.8% | 412.39M▲ 66.7% | 483.76M▲ 17.3% | 456.75M▼ 5.6% | 466.17M▲ 2.1% | 460.97M▼ 1.1% | 491.94M▲ 6.7% | 491.69M▲ 0% |
| Equity Growth % | -4.32% | 54.74% | -0.82% | 66.73% | 17.3% | -5.58% | 2.06% | -1.12% | 6.72% | 17.86% |
| Book Value per Share | 4.98 | 7.32 | 6.58 | 9.79 | 10.51 | 9.99 | 10.07 | 9.82 | 10.30 | 10.03 |
| Total Shareholders' Equity | 161.17M | 249.38M | 247.34M | 412.39M | 483.76M | 456.75M | 466.17M | 460.97M | 491.94M | 491.69M |
| Common Stock | 35K | 39K | 40K | 45K | 46K | 47K | 48K | 49K | 50K | 51K |
| Retained Earnings | -225.87M | -247M | -282.2M | -330.35M | -280.15M | -326.62M | -357.06M | -401.75M | -413.2M | -413.1M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 34K | -199K | -158K | 312K | -948K | -4.1M | -993K | -1.03M | 566K | 227K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATRC Cash Flow Statement
AtriCure, Inc. (ATRC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.94M | -4.17M | -15.81M | -19.87M | -13.78M | -22.14M | 4.48M | 12.2M | 57.33M | 57.33M |
| Operating CF Margin % | -5.12% | -2.07% | -6.85% | -9.62% | -5.02% | -6.7% | 1.12% | 2.62% | 10.73% | - |
| Operating CF Growth % | 40.84% | 53.37% | -279.07% | -25.67% | 30.65% | -60.67% | 120.25% | 172.17% | 369.8% | 533.39% |
| Net Income | -26.89M | -21.14M | -35.19M | -48.16M | 50.2M | -46.47M | -30.44M | 0 | -11.45M | -4.59M |
| Depreciation & Amortization | 9.13M | 8.75M | 9.37M | 9.55M | 10.44M | 11.71M | 14.81M | 0 | 20.53M | 20.72M |
| Stock-Based Compensation | 14.62M | 16.5M | 17.98M | 22.64M | 28.08M | 28.77M | 35.73M | 0 | 44.69M | 46.33M |
| Deferred Taxes | 21K | 724K | 445K | 1.51M | 84.78M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.81M | -10.41M | -3.79M | 1.22M | -182.43M | 2.72M | 2.62M | 30.56M | 7.85M | -13.41M |
| Working Capital Changes | -2M | 1.4M | -4.62M | -6.64M | -4.85M | -18.88M | -18.24M | -18.36M | -4.29M | 15.32M |
| Change in Receivables | -1.46M | -2.84M | -3.2M | 5.09M | -10.09M | -8.99M | -9.87M | -8.3M | -5.61M | -7.94M |
| Change in Inventory | -4.48M | -146K | -5.15M | -5.26M | -4.27M | -7.3M | -21.83M | -7.74M | -2.26M | -5.78M |
| Change in Payables | 1.29M | -2.4M | 2.79M | -1.56M | 4.71M | 2.68M | 6.18M | -1.53M | -960K | 5.33M |
| Cash from Investing | 3.76M | -85.4M | -2.15M | -156.2M | 23.5M | 44.01M | 21.82M | 30.23M | -14.55M | -16.72M |
| Capital Expenditures | -6.38M | -6.21M | -12.18M | -5.26M | -9.75M | -16.88M | -12M | 0 | -9.05M | -10.72M |
| CapEx % of Revenue | 3.65% | 3.08% | 5.28% | 2.55% | 3.56% | 5.11% | 3.01% | 5.04% | 1.69% | - |
| Acquisitions | 0 | 6K | -17.24M | 0 | -33.26M | -44.01M | 0 | 0 | 0 | -1M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 10.14M | 6K | 39K | 800K | 33.26M | 44.01M | -30M | 30.23M | -5.5M | -5M |
| Cash from Financing | 2.76M | 100.18M | 14.37M | 189.39M | -7.64M | -7.06M | -32K | -3.6M | 1.18M | -1.75M |
| Debt Issued (Net) | -1.69M | 15.63M | 19.87M | -667K | -816K | -899K | -992K | -1.67M | 5.05M | 287K |
| Equity Issued (Net) | -2.01M | 78.42M | -9.03M | 175.93M | -18.01M | -12.2M | -6.56M | -6.95M | -3.87M | 1.66M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -2.01M | -4.46M | -9.03M | -13.03M | -18.01M | -12.2M | -6.56M | -6.95M | -11.16M | -991K |
| Other Financing | 6.46M | 6.13M | 3.54M | 14.13M | 11.19M | 6.04M | 7.52M | 5.02M | 0 | -3.7M |
| Net Change in Cash | -2.4M▲ 0% | 10.42M▲ 534.4% | -3.75M▼ 136.0% | 13.46M▲ 459.2% | 1.71M▼ 87.3% | 14.45M▲ 744.7% | 26.21M▲ 81.5% | 38.41M▲ 46.5% | 44.71M▲ 16.4% | 46.28M▲ 0% |
| Free Cash Flow | -15.33M▲ 0% | -10.38M▲ 32.3% | -27.99M▼ 169.6% | -25.13M▲ 10.2% | -23.53M▲ 6.3% | -39.02M▼ 65.8% | -37.51M▲ 3.9% | -11.26M▲ 70.0% | 48.28M▲ 529.0% | 53.64M▲ 0% |
| FCF Margin % | -8.77% | -5.15% | -12.13% | -12.17% | -8.58% | -11.81% | -9.4% | -2.42% | 9.03% | 9.72% |
| FCF Growth % | 32.8% | 32.27% | -169.63% | 10.23% | 6.35% | -65.82% | 3.86% | 70% | 529% | 8082.59% |
| FCF per Share | -0.47 | -0.30 | -0.74 | -0.60 | -0.51 | -0.85 | -0.81 | -0.24 | 1.01 | 1.01 |
| FCF Conversion (FCF/Net Income) | 0.33x | 0.20x | 0.45x | 0.41x | -0.27x | 0.48x | -0.15x | -0.27x | -5.01x | -11.68x |
| Interest Paid | 2M | 3.87M | 3.72M | 4.37M | 4.22M | 4.27M | 6.38M | 5.95M | 0 | -1.25M |
| Taxes Paid | 37K | 65K | 259K | 217K | 190K | 192K | 395K | 619K | 0 | -116K |
ATRC Key Ratios
AtriCure, Inc. (ATRC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -16.32% | -10.3% | -14.17% | -14.6% | 11.2% | -9.88% | -6.6% | -9.64% | -2.4% | -0.95% |
| Return on Invested Capital (ROIC) | -10.41% | -5.76% | -8.8% | -8.97% | 8.62% | -6.47% | -4.31% | -6.89% | -0.63% | -0.63% |
| Gross Margin | 72.21% | 72.97% | 73.8% | 72.29% | 75.04% | 74.44% | 75.23% | 74.69% | 74.41% | 75.47% |
| Net Margin | -15.39% | -10.48% | -15.25% | -23.32% | 18.3% | -14.06% | -7.62% | -9.61% | -2.14% | -0.83% |
| Debt / Equity | 0.23x | 0.21x | 0.31x | 0.18x | 0.16x | 0.16x | 0.16x | 0.17x | 0.18x | 0.18x |
| Interest Coverage | -10.87x | -3.54x | -7.51x | -8.83x | 11.25x | -8.27x | -3.31x | -5.82x | -0.73x | 0.38x |
| FCF Conversion | 0.33x | 0.20x | 0.45x | 0.41x | -0.27x | 0.48x | -0.15x | -0.27x | -5.01x | -11.68x |
| Revenue Growth | 12.64% | 15.4% | 14.47% | -10.52% | 32.83% | 20.43% | 20.84% | 16.55% | 14.88% | 15.01% |
ATRC SEC Filings & Documents
AtriCure, Inc. (ATRC) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATRC Frequently Asked Questions
AtriCure, Inc. (ATRC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AtriCure, Inc. (ATRC) reported $552.2M in revenue for fiscal year 2025. This represents a 2782% increase from $19.2M in 2004.
AtriCure, Inc. (ATRC) grew revenue by 14.9% over the past year. This is steady growth.
AtriCure, Inc. (ATRC) reported a net loss of $4.6M for fiscal year 2025.
Dividend & Returns
AtriCure, Inc. (ATRC) has a return on equity (ROE) of -2.4%. Negative ROE indicates the company is unprofitable.
AtriCure, Inc. (ATRC) generated $53.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ATRC
AtriCure, Inc. (ATRC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates